Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07585565 Sodium Monosialotetrahexosylganglioside Motor Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07585565 Sodium Monosialotetrahexosylganglioside Motor Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07585565 clinical trial report covering Sodium Monosialotetrahexosylganglioside, Phase 2, endpoints, sponsor, geography, readout timing and development whi
Read →
NCT07583589 Dextromethorphan Hydrobromide Hydrate Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07583589 Dextromethorphan Hydrobromide Hydrate Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07583589 clinical trial report covering Dextromethorphan Hydrobromide Hydrate, Phase 2, endpoints, sponsor, geography, readout timing and development white
Read →
NCT07584018 Sintilimab Unresectable Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07584018 Sintilimab Unresectable Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07584018 clinical trial report covering Sintilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261893 DYX116 Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261893 DYX116 Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
CTR20261893 clinical trial report covering DYX116, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07583147 BAY-85-8102 Blood brain barrier defect Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07583147 BAY-85-8102 Blood brain barrier defect Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07583147 clinical trial report covering BAY-85-8102, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07583992 NRICM102 Community Acquired Pneumonia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07583992 NRICM102 Community Acquired Pneumonia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07583992 clinical trial report covering NRICM102, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07583862 Timolol Surgical Wound Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07583862 Timolol Surgical Wound Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07583862 clinical trial report covering Timolol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07583641 Efgartigimod Alfa Autoimmune Encephalitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07583641 Efgartigimod Alfa Autoimmune Encephalitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07583641 clinical trial report covering Efgartigimod Alfa, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07583745 Menaquinone 7 Calciphylaxis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07583745 Menaquinone 7 Calciphylaxis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07583745 clinical trial report covering Menaquinone 7, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261756 AP-306 Hyperphosphatemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261756 AP-306 Hyperphosphatemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
CTR20261756 clinical trial report covering AP-306, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07584967 AC-01 Reduced ejection fraction co-occurrent and due to chronic heart failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07584967 AC-01 Reduced ejection fraction co-occurrent and due to chronic heart failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07584967 clinical trial report covering AC-01, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07583810 Rituximab MALT lymphoma of stomach Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07583810 Rituximab MALT lymphoma of stomach Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07583810 clinical trial report covering Rituximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →